FOLH1 and neoplasm: Considering the preferable uptake profile of PSMA-1-DOTA, the next step is to start the preparations for pre-clinical studies to assess salivary and kidney uptake, damage (or lack-there-of), and tumor control using [225Ac]Ac-PSMA-1-DOTA.